Investor Relations

Neovasc, an OPKO Investee, Receives FDA Conditional Approval to Initiate TIARA-I Trial in U.S.: A Multinational, Multicenter Early Feasibility Trial of the TiaraTM Transcatheter Mitral Valve more »

OPKO Health Supports National Prostate Cancer Council Legislation more »

OPKO's Second Rayaldee Phase 3 Trial Meets Primary Endpoints more »

OPKO Launches the 4Kscore Test in Europe more »

Investor Relations

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put OPKO Health, Inc.'s financial performance into perspective.

  • Events


  • Stock Information


Ticker OPK Exchange NYSE
Last Price 8.36 Change 0.14 up
Open 8.25 Previous Close 8.22
Day High 8.40 Day Low 8.23
52-Week High 11.64 52-Week Low 7.32
Quotes delayed at least 20 minutes. Information provided by eSignal.